Gilead Sciences, Inc. (NASDAQ:GILD) Holdings Lowered by Alpha Omega Wealth Management LLC

Alpha Omega Wealth Management LLC lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 47,650 shares of the biopharmaceutical company’s stock after selling 626 shares during the quarter. Alpha Omega Wealth Management LLC’s holdings in Gilead Sciences were worth $3,490,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of GILD. Capital World Investors increased its position in shares of Gilead Sciences by 2.0% in the fourth quarter. Capital World Investors now owns 83,364,123 shares of the biopharmaceutical company’s stock worth $6,753,350,000 after acquiring an additional 1,642,736 shares in the last quarter. Capital Research Global Investors boosted its stake in Gilead Sciences by 3.0% in the 4th quarter. Capital Research Global Investors now owns 59,657,126 shares of the biopharmaceutical company’s stock worth $4,832,824,000 after purchasing an additional 1,743,418 shares during the period. Wellington Management Group LLP grew its position in Gilead Sciences by 14.4% during the 4th quarter. Wellington Management Group LLP now owns 18,630,134 shares of the biopharmaceutical company’s stock worth $1,509,227,000 after purchasing an additional 2,350,550 shares in the last quarter. Morgan Stanley raised its stake in Gilead Sciences by 0.9% during the 3rd quarter. Morgan Stanley now owns 16,909,619 shares of the biopharmaceutical company’s stock valued at $1,267,207,000 after purchasing an additional 158,794 shares during the period. Finally, Norges Bank purchased a new stake in shares of Gilead Sciences in the fourth quarter valued at $1,301,624,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the transaction, the insider now owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $68.61 on Friday. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. The firm has a fifty day simple moving average of $65.98 and a 200-day simple moving average of $72.58. The stock has a market capitalization of $85.48 billion, a price-to-earnings ratio of 190.58, a PEG ratio of 2.92 and a beta of 0.20. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $87.86.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. The company had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The business’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.37 earnings per share. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 3.75 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Shareholders of record on Friday, June 14th were given a $0.77 dividend. This represents a $3.08 annualized dividend and a yield of 4.49%. The ex-dividend date of this dividend was Friday, June 14th. Gilead Sciences’s dividend payout ratio is currently 855.56%.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of research analyst reports. HSBC upgraded Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target on the stock in a report on Wednesday, April 24th. Maxim Group dropped their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Wednesday, May 1st. Robert W. Baird restated a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a report on Thursday, June 20th. Barclays cut their target price on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating for the company in a research report on Monday, April 29th. Finally, Royal Bank of Canada restated a “sector perform” rating and set a $74.00 price target on shares of Gilead Sciences in a report on Friday, June 14th. Twelve investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $83.47.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.